KYMR
Kymera Therapeutics, Inc.
Biotechnology · Healthcare · United States
126.63
close · 2026-10-30
value
80
cheaper than peers80
quality
90
stronger fundamentals90
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | -2.0% | 83 |
| earnings yield, 3 years ago | -2.3% | 82 |
| cash flow yield, 3 years ago | -1.4% | 79 |
| earnings yield, 1 year ago | -2.4% | 78 |
| cash flow yield, 2 years ago | -1.3% | 78 |
| cash flow yield, 1 year ago | -1.9% | 77 |
| cash flow yield, latest year | -2.2% | 73 |
| earnings yield, latest year | -2.9% | 72 |
| price to book | 6.69× | 27 |
| price to sales | 102.96× | 13 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 466.4% | 91 |
| debt to equity | 5.2% | 72 |
| return on equity | -24.2% | 71 |
| operating margin | -116.3% | 54 |
4 of 4 measures available
Facts
| market cap | $11B |
| free cash flow | -$144.1M |
| employees | 273 |
| first trade | 2020-08-21 |
| next earnings | 2026-10-29 |
| fundamentals updated | 2026-10-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.69 | -2.98 | -2.52 | -2.87 |
| free cash flow | -$234.3M | -$207.3M | -$137.3M | -$155.9M |
| net income | -$311.4M | -$223.9M | -$147.0M | -$154.8M |
| revenue | $39.2M | $47.1M | $78.6M | $46.8M |
| unusual items | -$3.9M | -$4.9M | $0 | $0 |